RT Journal Article
T1 Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.
A1 Rodriguez-Peralvarez, Manuel
A1 Amado, Victor
A1 de la Mata, Manuel
AB We read with great interest the meta‐analysis by Grigg et al,1  which evaluated the role of the mechanistic target of rapamycin (mTOR) inhibitors (sirolimus or everolimus) in patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). The authors found that mTOR‐inhibitor based immunosuppression was associated with prolonged recurrence‐free and overall survival. Although these findings could motivate the reader to systematically prescribe mTOR inhibitors in patients with HCC, there are some important considerations to be taken into account first.
PB Wiley-Blackwell Publishing
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14335
UL http://hdl.handle.net/10668/14335
LA en
NO Rodríguez-Perálvarez M, Amado V, de la Mata M. Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation. Aliment Pharmacol Ther. 2019 Aug;50(4):478-479
DS RISalud
RD Apr 9, 2025